Barts hospital running a Trial looking at Active Surveillance
Monday, 10th July 2017
Barts Hospital London are currently running a Prostate Cancer clinical trial looking at how to stop low and intermediate prostate cancer from developing into high risk cancer. The PROVENT study is a clinical trial for men diagnosed with prostate cancer who are on active surveillance. It aims to test whether Aspirin and/or Vitamin D3 have the potential to stop low and intermediate risk prostate cancers from developing into high risk cancers.
Homerton University Hospital, University College London Hospital, St Bartholomew’s Hospital and University Hospital Coventry are all currently recruiting participants to the study. Men whose prostate cancer is being managed via active surveillance in any of the aforementioned hospitals are advise to contact the team in charge of their care if they are interested in joining the study.
More information about the study can be found at the PROVENT website www.provent.org.uk
With best regards,
Senior Trials Recruitment Co-ordinator email@example.com
Barts Clinical Trials Unit, Centre for Cancer Prevention Queen Mary University of London
Wolfson Institute of Preventive Medicine | Charterhouse Square | London EC1M 6BQ
Tel +44 (0)20 7882 3834| Fax +44 (0)20 7882 3886 | Barts CTU
No upcoming events.
OWise Announce Launch of Prostate Cancer App
29 Mar 2021